Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus CHOP in Relapsed Mantle Cell Lymphoma
NCT00513955Phase 2Completed
- Sponsor
- University Hospitals Plymouth
- Start
- Jun 2006
- Primary completion
- Oct 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in mantle cell lymphoma (MCL) (2 arms), sponsored by University Hospitals Plymouth. Primary endpoint: Overall Response Rate. Started Jun 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00513955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00513955.